000			01513 a2200421 4500
005			20250514212528.0
264		0	_c20050412
008			200504s 0 0 eng d
022			_a0021-972X
024	7		_a10.1210/jc.2004-0952 _2doi
040			_aNLM _beng _cNLM
100	1		_aOdvina, Clarita V
245	0	0	_aSeverely suppressed bone turnover: a potential complication of alendronate therapy. _h[electronic resource]
260			_bThe Journal of clinical endocrinology and metabolism _cMar 2005
300			_a1294-301 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAged
650	0	4	_aAlendronate _xadverse effects
650	0	4	_aBiopsy
650	0	4	_aBone Density _xdrug effects
650	0	4	_aBone Resorption _xchemically induced
650	0	4	_aFemale
650	0	4	_aFracture Healing
650	0	4	_aFractures, Bone _xetiology
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOsteoclasts _xdrug effects
650	0	4	_aOsteoporosis _xdrug therapy
650	0	4	_aSeverity of Illness Index
700	1		_aZerwekh, Joseph E
700	1		_aRao, D Sudhaker
700	1		_aMaalouf, Naim
700	1		_aGottschalk, Frank A
700	1		_aPak, Charles Y C
773	0		_tThe Journal of clinical endocrinology and metabolism _gvol. 90 _gno. 3 _gp. 1294-301
856	4	0	_uhttps://doi.org/10.1210/jc.2004-0952 _zAvailable from publisher's website
999			_c15281128 _d15281128